Chemokine receptor binding polypeptides

Patent metadata

Field	Value
Publication number	US-9328174-B2
Application number	US-201313886530-A
Country	US
Kind code	B2
Filing date	May 3, 2013
Priority date	May 9, 2012
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

First claim

The invention claimed is:

1. A polypeptide comprising the amino acid sequence of SEQ ID NO:221 and a C-terminal extension consisting of two alanine residues.

2. A polypeptide comprising the amino acid sequence of SEQ ID NO:222 and a C-terminal extension consisting of two alanine residues.

3. A polypeptide comprising the amino acid sequence of SEQ ID NO:223 and a C-terminal extension consisting of two alanine residues.

4. A polypeptide comprising the amino acid sequence of SEQ ID NO:224 and a C-terminal extension consisting of two alanine residues.

5. A polypeptide comprising a first antigen binding domain comprising the amino acid sequence of SEQ ID NO:219, and a second antigen binding domain comprising the amino acid sequence of SEQ ID NO:215, wherein the first antigen binding domain and second antigen binding domain are separated by a linker comprising the amino acid sequence of SEQ ID NO:220, and a C-terminal extension consisting of two alanine residues.

6. A polypeptide comprising the amino acid sequence of SEQ ID NO:225 and a C-terminal extension consisting of two alanine residues.

7. A pharmaceutical composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier or diluent.

8. A polypeptide comprising a first antigen binding domain comprising the amino acid sequence of SEQ ID NO:216, and a second antigen binding domain comprising the amino acid sequence of SEQ ID NO:217, wherein the first antigen binding domain and second antigen binding domain are separated by a linker comprising the amino acid sequence of SEQ ID NO:220, and a C-terminal extension consisting of two alanine residues.

9. A pharmaceutical composition comprising the polypeptide of claim 8 and a pharmaceutically acceptable carrier or diluent.

10. A polypeptide comprising a first antigen binding domain, wherein the first antigen binding domain comprises three CDRS comprising the amino acid sequences of SEQ ID NOs:141, 236, and 181, a second antigen binding domain, wherein the second antigen binding domain comprises three CDRS comprising the amino acid sequences of SEQ ID NOs: 146, 237, and 186, wherein the first antibody binding domain and second antigen binding domain are separated by a linker comprising the amino acid sequence of SEQ ID NO:220, and a C-terminal extension consisting of two alanine residues.

11. A pharmaceutical composition comprising the polypeptide of claim 10 and a pharmaceutically acceptable carrier or diluent.

Assignees

• Novartis Ag

Inventors

• Brown Zarin
• Bradley Michelle
• Charlton Steven John
• Van Heeke Gino Anselmus
• Cromie Karen
• Dombrecht Bruno
• Steffensen Soren
• Baumeister Judith
• Bouche Marie-Paule
• Boutton Carlo
• Buyse Marie-Ange
• Snoeck Veerle
• Staelens Stephanie

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title